Susan Suponcic Joins Navigant to Lead Life Sciences' Global Market Access Center of Excellence

Industry executive brings global pricing, health economics and market access expertise

Wednesday, February 11, 2015

Email to a Friend
Today, Navigant (NYSE: NCI) announced that Susan J. Suponcic, Ph.D., has joined the Navigant Life Sciences practice as Managing Director and leader of the Global Market Access Center of Excellence. In her role, Dr. Suponcic will assist Life Sciences clients with strategic initiatives to optimize, substantiate and capture the value of their innovations across dynamic and demanding global market access environments.

Dr. Suponcic brings nearly two decades of experience delivering measurable and impactful business results through global pricing, health economics and market access initiatives both as a pharmaceutical company executive and industry consultant. Most recently, she led the global market access practice at Kantar Health, a WPP company. She spent more than 10 years at Johnson & Johnson, and, served as Vice President of Worldwide Health Economics & Pricing where she led multiple global teams to align global strategic marketing, pharmaceutical R&D, local and global operating companies on market access strategy and implementation. She has managed pricing, reimbursement and access initiatives for multiple global pharmaceutical product launches.

"We look forward to leveraging Susan's global experience and leadership in pricing and reimbursement to enhance our reputation as one of the most innovative and insightful consulting practices within this complex marketplace," said Eduardo Schur, Managing Director and global leader of Navigant's Life Sciences practice. "Navigant will continue to aggressively invest in market access to assist our clients in securing patient access to innovative products addressing unmet medical needs."

Dr. Suponcic received her Ph.D. in Managerial Science and Applied Economics from The Wharton School, University of Pennsylvania; an M.Sc. in Public Policy and Administration from the London School of Economics and Political Science, University of London; and a B.A. in Economics from Trinity University in Texas. She is based within Navigant's Princeton, NJ office.

"I am thrilled to be joining Navigant's Life Sciences practice during this time of considerable change in healthcare" said Dr. Suponcic. "I look forward to working with the talented team of experts at Navigant to build greater capabilities and to further establish our presence in this dynamic and growing area within Life Sciences."

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.